Matinas BioPharma Holdings Inc (MTNB) Short Interest Up 25.7% in January

Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) was the recipient of a large increase in short interest in the month of January. As of January 31st, there was short interest totalling 5,721,565 shares, an increase of 25.7% from the January 15th total of 4,550,674 shares. Currently, 6.0% of the company’s stock are short sold. Based on an average daily volume of 961,409 shares, the short-interest ratio is presently 6.0 days.

Several equities research analysts have commented on the stock. Maxim Group boosted their price target on shares of Matinas BioPharma from $2.00 to $5.00 and gave the stock a “buy” rating in a research report on Monday, November 12th. Roth Capital assumed coverage on shares of Matinas BioPharma in a report on Monday. They issued a “buy” rating and a $4.75 target price on the stock.

Several institutional investors have recently made changes to their positions in the company. IFP Advisors Inc grew its position in Matinas BioPharma by 222.0% during the 4th quarter. IFP Advisors Inc now owns 1,775,000 shares of the company’s stock valued at $1,083,000 after purchasing an additional 1,223,828 shares during the last quarter. BlackRock Inc. raised its stake in Matinas BioPharma by 147.1% during the 4th quarter. BlackRock Inc. now owns 290,589 shares of the company’s stock worth $173,000 after acquiring an additional 173,005 shares during the period. K.J. Harrison & Partners Inc bought a new stake in Matinas BioPharma during the 3rd quarter worth approximately $150,000. Renaissance Technologies LLC raised its stake in Matinas BioPharma by 325.6% during the 3rd quarter. Renaissance Technologies LLC now owns 134,900 shares of the company’s stock worth $124,000 after acquiring an additional 103,200 shares during the period. Finally, Virtu Financial LLC bought a new stake in Matinas BioPharma during the 4th quarter worth approximately $39,000.

Matinas BioPharma stock traded up $0.05 during trading hours on Monday, hitting $1.08. The company had a trading volume of 665,805 shares, compared to its average volume of 1,041,475. Matinas BioPharma has a one year low of $0.32 and a one year high of $1.48.

Matinas BioPharma (NYSEAMERICAN:MTNB) last announced its quarterly earnings data on Monday, November 12th. The company reported ($0.03) earnings per share (EPS) for the quarter.

COPYRIGHT VIOLATION WARNING: This piece of content was posted by WKRB News and is the sole property of of WKRB News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of international copyright laws. The legal version of this piece of content can be accessed at

About Matinas BioPharma

Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable.

See Also: Diversification Important in Investing

Receive News & Ratings for Matinas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma and related companies with's FREE daily email newsletter.

Leave a Reply